Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute for Cancer Research

Eureka Therapeutics, Inc.

David Spriggs

Dharmarao Thapi

Samuel J Danishefsky

Philip O Livingston

Hong Liu

Alberto Fernandez-Tejada

Govind Ragupathi

Javier Morales

Yoko Nakano

Jianglong Zhu

Marina Stasenko

Alberto Fernandez-tejada

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Antibodies to galectin-3 and methods of use thereof

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.

Antibodies to MUC16 and methods of use thereof

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Anti-MUC16 antibodies and uses thereof

Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.

Multivalent glycopeptide constructs and uses thereof

Growing community of inventors

New York, NY, United States of America

David Spriggs